![]() |
|
|
Vol. 285, Issue 3, 1197-1206, June 1998
Departments of
Psychology (E.A.W., L.A.D.) and
Pharmacology
(L.A.D.),
Curriculum in Neurobiology (R.M.A., L.A.D.), University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina; and
Department of Psychology (R.C.P.), University of North Carolina at
Wilmington, Wilmington, North Carolina
The opioid agonists morphine, etorphine, buprenorphine and U50,488 were
examined alone and in combination with the insurmountable opioid
antagonist clocinnamox (C-CAM) in squirrel monkeys responding under a
schedule of shock titration. In this procedure, shock intensity
increased every 15 sec from 0.01 to 2.0 mA in 30 increments. Five lever
presses during any given 15-sec shock period produced a 15-sec timeout,
after which shock resumed at the next lower intensity. When given
alone, each of these agonists increased the median intensity at which
the monkeys maintained shock [median shock level (MSL)]. At the
highest dose examined alone, each agonist produced maximal increases in
MSL and, except buprenorphine, decreased response rates. C-CAM
dose-dependently antagonized the effects of morphine, etorphine and
buprenorphine on MSL. In the presence of the higher C-CAM doses,
etorphine, morphine and buprenorphine did not produce maximal effects
on MSL. The effects of U50,488 were not systematically altered when
tested in combination with the highest C-CAM dose. In general, C-CAM
was more potent and the duration of antagonism was slightly longer
against buprenorphine than against morphine and etorphine. Quantitative
analysis of these data according to an extended model of
yielded the following apparent affinity and efficacy estimates,
respectively: etorphine (0.085 mg/kg, 117); morphine (49 mg/kg, 24) and
buprenorphine (0.62 mg/kg, 7.1). Determination of the individual q
values over time indicated that the receptor population recovers more
quickly after C-CAM antagonism of etorphine than from C-CAM antagonism
of either morphine or buprenorphine. These data suggest that C-CAM
functions as a long-lasting antagonist of mu opioid
agonist actions in a shock titration procedure and yields estimates of
relative intrinsic efficacy with the rank order of etorphine > morphine > buprenorphine.
This article has been cited by other articles:
![]() |
S. D. Comer, M. A. Sullivan, and E. A. Walker Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen, A. L. Granger, and L. A. Dykstra The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Barrett, E. S. Smith, and M. J. Picker Use of Irreversible Antagonists to Determine the Relative Efficacy of {micro}-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of {beta}-Funaltrexamine and Clocinnamox J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1061 - 1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen and L. A. Dykstra N-Methyl-D-Aspartate Receptor Antagonists Potentiate the Antinociceptive Effects of Morphine in Squirrel Monkeys J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 288 - 297. [Abstract] [Full Text] |
||||
![]() |
R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text] |
||||
![]() |
M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653. [Abstract] [Full Text] |
||||